Article
Oncology
Julie R. Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D. Santomasso, Satish P. Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff
Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Tim F. Greten, Ghassan K. Abou-Alfa, Ann-Lii Cheng, Austin G. Duffy, Anthony B. El-Khoueiry, Richard S. Finn, Peter R. Galle, Lipika Goyal, Aiwu Ruth He, Ahmed O. Kaseb, Robin Kate Kelley, Riccardo Lencioni, Amaia Lujambio, Donna Mabry Hrones, David J. Pinato, Bruno Sangro, Roberto Troisi, Andrea Wilson Woods, Thomas Yau, Andrew X. Zhu, Ignacio Melero
Summary: The standard of care for advanced HCC has been transformed by the combination of immunotherapy and anti-VEGF therapy, showing improved overall survival rates. The use of immunotherapy in later stages of treatment has been proven safe and effective, with ongoing research focusing on novel combinations of ICI and TKI for earlier intervention in HCC treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Leisha A. Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L. Disis, Margaret E. Gatti-Mays, Alice Y. Ho, Kevin Kalinsky, Heather L. McArthur, Elizabeth A. Mittendorf, Rita Nanda, David B. Page, Hope S. Rugo, Krista M. Rubin, Hatem Soliman, Patricia A. Spears, Sara M. Tolaney, Jennifer K. Litton
Summary: In recent years, the use of immune checkpoint inhibitors in combination with chemotherapy for advanced/metastatic TNBC has shown efficacy, leading to FDA approval and expanding treatment options for patients. Questions remain regarding optimal chemotherapy backbone, patient selection, and treatment strategies, highlighting the importance of further research and guidance for healthcare providers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Ann W. Silk, Christopher A. Barker, Shailender Bhatia, Kathryn B. Bollin, Sunandana Chandra, Zeynep Eroglu, Brian R. Gastman, Kari L. Kendra, Harriet Kluger, Evan J. Lipson, Kathleen Madden, David M. Miller, Paul Nghiem, Anna C. Pavlick, Igor Puzanov, Guilherme Rabinowits, Emily S. Ruiz, Vernon K. Sondak, Edward A. Tavss, Michael T. Tetzlaff, Isaac Brownell
Summary: Nonmelanoma skin cancers (NMSCs) are commonly diagnosed malignancies, with some patients facing more challenging treatment. Immune checkpoint inhibitors (ICIs) have shown activity against NMSCs, but their clinical use may be more challenging due to various factors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Matthew D. Galsky, Arjun Balar, Peter C. Black, Matthew T. Campbell, Gail S. Dykstra, Petros Grivas, Shilpa Gupta, Christoper J. Hoimes, Lidia P. Lopez, Joshua J. Meeks, Elizabeth R. Plimack, Jonathan E. Rosenberg, Neal Shore, Gary D. Steinberg, Ashish M. Kamat
Summary: Immunotherapies play a significant role in the treatment of urothelial cancer, with a focus on selecting the right agents and treatment scheduling while considering patient management. A panel of experts has developed a clinical practice guideline to provide guidance for healthcare professionals treating patients with urothelial cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Michael B. Atkins, Hamzah Abu-Sbeih, Paolo A. Ascierto, Michael R. Bishop, Daniel S. Chen, Madhav Dhodapkar, Leisha A. Emens, Marc S. Ernstoff, Robert L. Ferris, Tim F. Greten, James L. Gulley, Roy S. Herbst, Rachel W. Humphrey, James Larkin, Kim A. Margolin, Luca Mazzarella, Suresh S. Ramalingam, Meredith M. Regan, Brian Rini, Mario Sznol
Summary: The activity of agents blocking PD-(L)1 axis has revolutionized oncology, but not all patients benefit from these therapies. Many drug development programs have combined anti-PD-(L)1 with other therapies, but there is a lack of predictive biomarkers and optimized clinical trial designs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Ramaswamy Govindan, Charu Aggarwal, Scott J. Antonia, Marianne Davies, Steven M. Dubinett, Andrea Ferris, Patrick M. Forde, Edward B. Garon, Sarah B. Goldberg, Raffit Hassan, Matthew D. Hellmann, Fred R. Hirsch, Melissa L. Johnson, Shakun Malik, Daniel Morgensztern, Joel W. Neal, Jyoti D. Patel, David L. Rimm, Sarah Sagorsky, Lawrence H. Schwartz, Boris Sepesi, Roy S. Herbst
Summary: Immunotherapy has significantly impacted lung cancer care, providing durable responses and extended survival outcomes in various treatment settings. Although challenges remain in therapy selection, biomarker identification, special patient populations, and toxicity management, education and support for patients and caregivers are crucial for maximizing the benefits of immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Ophthalmology
Hiroshi Takase, Nisha R. Acharya, Kalpana Babu, Bahram Bodaghi, Moncef Khairallah, Peter J. McCluskey, Nattaporn Tesavibul, Jennifer E. Thorne, Ilknur Tugal-Tutkun, Joyce H. Yamamoto, Narsing A. Rao, Justine R. Smith, Manabu Mochizuki
Summary: Expert recommendations for the management of ocular sarcoidosis were established through a survey and consensus workshop, covering evaluation and monitoring of inflammation, indications for treatment, and the management of different types of uveitis, as well as the use of systemic corticosteroids and immunosuppressive drugs.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Oncology
David Hsiehchen, Magdalena Espinoza, Cristina Valero, Chul Ahn, Luc G. T. Morris
Summary: The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden of at least 10 mut/Mb is predicted to reduce healthcare disparities by broadening treatment eligibility. Lowering TMB thresholds can increase the eligibility of minority patients for immune checkpoint inhibitors while maintaining the predictive value of treatment benefit. This study shows variations in TMB-high cancers between racial groups and offers guidance in developing more rational eligibility criteria for immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Stanislav Fridland, Jaeyoun Choi, Myungwoo Nam, Samuel Joseph Schellenberg, Eugene Kim, Grace Lee, Nathaniel Yoon, Young Kwang Chae
Summary: Tissue tumor mutational burden (tTMB) and blood TMB (bTMB) predict treatment responses differently, with bTMB potentially reflecting tumor heterogeneity. Comprehensively considering both TMB and tumor heterogeneity is important for predicting treatment responses accurately.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Rheumatology
Jason S. Kim, Silvana Borges, Daniel J. Clauw, Philip G. Conaghan, David T. Felson, Thomas R. Fleming, Rachel Glaser, Elizabeth Hart, Marc Hochberg, Yura Kim, Virginia B. Kraus, Larissa Lapteva, Xiaojuan Li, Sharmila Majumdar, Timothy E. McAlindon, Ali Mobasheri, Tuhina Neogi, Frank W. Roemer, Rebecca Rothwell, Robert Shibuya, Jeffrey Siegel, Lee S. Simon, Kurt P. Spindler, Nikolay P. Nikolov
Summary: This article summarizes a workshop on osteoarthritis, discussing the current state of science, identifying knowledge gaps, and examining developmental and regulatory challenges in bringing these products to market.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Rheumatology
Jason S. Kim, Silvana Borges, Daniel J. Clauw, Philip G. Conaghan, David T. Felson, Thomas R. Fleming, Rachel Glaser, Elizabeth Hart, Marc Hochberg, Yura Kim, Virginia B. Kraus, Larissa Lapteva, Xiaojuan Li, Sharmila Majumdar, Timothy E. McAlindon, Ali Mobasheri, Tuhina Neogi, Frank W. Roemer, Rebecca Rothwell, Robert Shibuya, Jeffrey Siegel, Lee S. Simon, Kurt P. Spindler, Nikolay P. Nikolov
Summary: OA is a challenging disease to develop therapeutics for, with a high failure rate in efficacy clinical trials, and the need for better clinical endpoints to reflect disease modification.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Oncology
Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross
Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine Cohen, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Keith Flaherty, Ryan Sullivan, Jun Guo, Genevieve Boland
Summary: This study analyzed the radiological dynamics and clinical manifestations of primary and secondary resistance to anti-PD-1 therapy in patients with advanced melanoma, finding that different resistance subtypes significantly impact survival outcomes and provide important insights for clinical decision-making and trial design.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Clinical Neurology
Sarinnapha M. Vasunilashorn, Nadia Lunardi, John C. Newman, Gregory Crosby, Leah Acker, Ted Abel, Seema Bhatnagar, Colm Cunningham, Rafael de Cabo, Laura Dugan, Joseph A. Hippensteel, Yumiko Ishizawa, Shouri Lahiri, Edward R. Marcantonio, Zhongcong Xie, Sharon K. Inouye, Niccolo Terrando, Roderic G. Eckenhoff
Summary: Delirium is a common, morbid, and costly syndrome closely associated with Alzheimer's disease (AD) and AD-related dementias (ADRD). While human studies have improved our understanding of delirium in terms of incidence, risk factors, outcomes, and management, limited knowledge exists about the neurobiology of delirium. This article discusses the use of preclinical and translational animal models to advance our understanding of delirium neurobiology and develop new prevention and treatment strategies. Recommendations for the development and validation of these models are provided to enhance awareness in this important field.
ALZHEIMERS & DEMENTIA
(2023)
Article
Allergy
T. Fulop, A. Larbi, G. Pawelec, A. Khalil, A. A. Cohen, K. Hirokawa, J. M. Witkowski, C. Franceschi
Summary: The concept of inflammaging introduced by Prof. Franceschi in 2000 revolutionized the understanding of immune changes in response to lifelong stress. It highlights the dichotomy of the proinflammatory process, influenced by genetics and the environment, leading to either beneficial or detrimental consequences. Moreover, it elucidates the complex and systemic nature of aging, opening avenues for studying counter-processes in addition to the process itself. This concept also paves the way for potential multimodal interventions to optimize aging towards healthy longevity.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
(2023)
Article
Geriatrics & Gerontology
Nikolaus Buchmann, Jens Fielitz, Dominik Spira, Maximilian Koenig, Kristina Norman, Graham Pawelec, David Goldeck, Ilja Demuth, Elisabeth Steinhagen-Thiessen
Summary: The study found that inflammation is associated with lower muscle mass, particularly in individuals with Metabolic syndrome (MetS). Controlling MetS may help prevent sarcopenia.
Article
Geriatrics & Gerontology
Emilie Picard, Sarah Armstrong, Melissa K. Andrew, Laura Haynes, Mark Loeb, Graham Pawelec, George A. Kuchel, Janet E. McElhaney, Chris P. Verschoor
Summary: The study found a significant association between systemic inflammation levels and antibody responses to the seasonal influenza vaccine, particularly in older adults receiving high vaccine doses.
Article
Oncology
Christianne Groeneveldt, Priscilla Kinderman, Jordi J. C. van Stigt Thans, Camilla Labrie, Lisa Griffioen, Marjolein Sluijter, Diana J. M. van den Wollenberg, Rob C. Hoeben, Joke M. M. den Haan, Sjoerd H. van Der Burg, Thorbald van Hall, Nadine van Montfoort
Summary: The study shows that primed reovirus-specific T cells can be used as potent effector cells for anticancer treatment. By designing a synthetic long peptide vaccination strategy, the intratumoral frequency of these specific T cells can be enhanced.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Shidi Wu, Marion Rietveld, Marieke Hogervorst, Frank de Gruijl, Sjoerd van der Burg, Maarten Vermeer, Remco van Doorn, Marij Welters, Abdoelwaheb El Ghalbzouri
Summary: The study demonstrated that papillary and reticular fibroblasts in the dermis have distinct effects on epithelial/non-epithelial tumors, particularly in promoting EMT and invasion processes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Juraj Adamik, Paul Munson, Felix J. Hartmann, Alexis J. Combes, Philippe Pierre, Matthew F. Krummel, Sean C. Bendall, Rafael J. Arguello, Lisa H. Butterfield
Summary: Assessing metabolic activity at the single-cell level provides important insights into the immune profiles of human dendritic cells. This study reveals the metabolic differences between immune stimulatory and tolerogenic dendritic cells, and highlights the simultaneous engagement of multiple metabolic pathways in distinct stages of dendritic cell differentiation.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
C. Stingl, S. P. Lau, S. H. van der Burg, J. G. Aerts, C. H. J. van Eijck, T. M. Luider
Summary: This study used proteomics analysis to investigate the potential of tumor-reactive T-cell response through vaccination of pancreatic cancer patients with an allogenic tumor cell lysate vaccine. The results identified 61 tumor antigens and quantified them using TMT labels.
Article
Oncology
Anna M. Di Giacomo, Maximilian J. Mair, Michele Ceccarelli, Andrea Anichini, Ramy Ibrahim, Michael Weller, Michael Lahn, Alexander M. M. Eggermont, Bernard Fox, Michele Maio
Summary: The conditions that promote immunotherapy responses in primary or secondary brain malignancies were discussed during the V Siena Immuno-Oncology (IO) Think Tank meeting in 2021. Important publications in 2021 and 2022 have reinforced the core elements of these discussions. While current immunotherapies have failed to benefit patients with primary brain tumors like glioblastoma, they have shown positive responses in brain metastases. The differences between these conditions seem to be influenced by intrinsic and extrinsic factors, such as driver mutations, the blood-brain barrier, and the immune suppressive microenvironment. Future therapeutic interventions may focus on rebalancing the immune cell population to enable better responses to current and future immunotherapies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Bernhard Mlecnik, Alessandro Lugli, Gabriela Bindea, Florence Marliot, Carlo Bifulco, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T. Rau, Martin D. Berger, Iris D. Nagtegaal, Elisa Vink-Borger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grutzmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Leonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H. A. Roehrl, Pamela S. Ohashi, Linh T. Nguyen, SeongJun Han, Heather L. MacGregor, Sara Hafezi-Bakhtiari, Bradly G. Wouters, Giuseppe Masucci, Emilia K. Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Benedicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon Van Lent-van Vliet, Nikki Knijn, Ana-Maria Musing, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Prabhu Patel, Hemangini H. Vora, Birva Shah, Jayendrakumar B. Patel, Kruti N. Rajvik, Shashank J. Pandya, Shilin N. Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M. Marincola, Paolo A. Ascierto, Bernard A. Fox, Franck Pages, Jerome Galon
Summary: This study found that the immune system status is a better predictor of prognosis in early-stage colon cancer patients than tumor cell-related parameters. The consensus Immunoscore accurately identifies early-stage colon cancer patients with different clinical outcomes, regardless of treatment bias.
Article
Virology
Maria Grazia Cusi, Anna Maria Di Giacomo, Gabriele Anichini, Gianni Gori Savellini, Chiara Terrosi, Claudia Gandolfo, Michele Maio
Summary: This study presents the case of a 76-year-old male patient with persistent infection of SARS-CoV-2 in the context of cutaneous melanoma and non-Hodgkin's lymphoma. Cancer treatments were discontinued due to persistent COVID-19. The patient was treated with sotrovimab, but acquired resistance mutations made it ineffective. In vitro screening of Evusheld monoclonal antibodies against the patient's viral strains led to successful therapy and allowed the patient to resume cancer treatment.
Article
Oncology
Xiaoyu Li, Jingjing Li, Yue Zheng, Sandra J. Lee, Jun Zhou, Anita Giobbie-Hurder, Lisa H. Butterfield, Glenn Dranoff, F. Stephen Hodi
Summary: With the successful development of immune checkpoint blockade, the addition of granulocyte-macrophage-CSF (GM-CSF) has been shown to improve efficacy and decrease adverse events. The presence of ICOS+CD4+ or ICOS+CD8+ T cells in the peripheral blood is significantly higher in patients treated with ipilimumab plus GM-CSF compared to those treated with ipilimumab alone. Soluble ICOS splice variants have suppressive effects and can serve as a biomarker for GM-CSF and immune checkpoint blockade-based therapies.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Oncology
Marit J. van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J. C. van Stigt Thans, Thorbald Van Hall, Sjoerd H. van der Burg
Summary: A small population of CD163(hi) tissue-resident macrophages is identified to be responsible for primary and secondary resistance against T-cell-based immunotherapies. While these CD163(hi) M2 macrophages are resistant to Csf1r-targeted therapies, in-depth characterization and identification of the underlying mechanisms driving immunotherapy resistance allows the specific targeting of this subset of macrophages, thereby creating new opportunities for therapeutic intervention with the aim to overcome immunotherapy resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Lisa H. Butterfield, Yana G. Najjar
Summary: The approval of immune checkpoint inhibitors has shifted the treatment paradigm for malignancies. Combination therapies and biomarker studies are important for maximizing clinical efficacy.
NATURE REVIEWS IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Juraj Adamik, Paul V. Munson, Deena M. Maurer, Felix J. Hartmann, Sean C. Bendall, Rafael J. Arguello, Lisa H. Butterfield
Summary: This study analyzed the transcriptomic and immune-metabolic profiles of dendritic cells (DCs) from patients with late-stage melanoma. The results suggest that the metabolic profile of DCs is associated with the immunostimulatory potential of cancer vaccines.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Jian Ye, Weihua Guo, Chongkai Wang, Colt A. Egelston, Massimo D'Apuzzo, Geereesh Shankar, Marwan G. Fakih, Peter P. Lee
Summary: Our study reveals significant variations in functional status and spatial distribution of immune cells across different metastatic sites in MSS colorectal cancer. These findings suggest that metastatic site-dependent immune contexture may underlie discordant responses to ICI therapy in patients with MSS colorectal cancer.
CANCER RESEARCH COMMUNICATIONS
(2023)